NEW YORK (GenomeWeb) – Swedish drug discovery firm Pelago Bioscience and German proteomics firm OmicScouts today announced a collaboration to determine and quantify drug interactions using Pelago's cellular thermal shift assay (CETSA) technology.

Under the terms of the agreement, Pelago has licensed its CETSA technology to OmicScouts for mass spectrometric and proteomic applications for contract research projects. The firms will combine expertise and resources to offer target identification and validation services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.